首页 > 市场调查报告书 > 医疗设备

体外诊断癌症

北美肺癌筛检市场预测至 2030 年 - 区域分析 - 按癌症类型、技术、年龄层（50 岁及以上和 50 岁以下）和最终用户（医院、诊断中心等）

市场调查报告书

商品编码

1402531

北美肺癌筛检市场预测至 2030 年 - 区域分析 - 按癌症类型、技术、年龄层（50 岁及以上和 50 岁以下）和最终用户（医院、诊断中心等）

North America Lung Cancer Screening Market Forecast to 2030 - Regional Analysis - by Cancer Type, Technology, Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

出版日期: 2023年11月07日 | 出版商:

The Insight Partners | 英文 100 Pages | 订单完成后即时交付

价格

简介目录图表

北美肺癌筛检市场预计将从2022年的9.6541亿美元成长到2030年的18.1148亿美元。预计2022年至2030年CAGR为8.2%。

不断增加的政府支持推动了北美肺癌筛检市场。

肺癌是全世界死亡的主要原因之一。肺癌筛检是癌症预防方法的重要组成部分。早期诊断出肺癌患者的预后会更好，因此鼓励肺癌高风险族群进行常规检查，以检测肺部癌性生长的形成。根据美国癌症协会估计，2023年美国肺癌新病例约238,340例；其中，女性 120,790 人，男性 117,550 人。因此，全球肺癌发生率的上升推动了肺癌筛检计画的启动，这反过来又推动了市场的成长。

北美肺癌筛检市场概况

北美肺癌筛检市场分为美国、加拿大和墨西哥。该地区的增长归因于多种因素，例如肺癌发病率的增加以及人们对吸烟副作用的认识。此外，政府对筛检的支持不断增加，导致市场进一步成长。

在北美，美国在北美肺癌筛检市场中占有重要份额。该国的市场成长主要是由肺癌发病率上升和政府措施推动的。肺癌是美国男性和女性第二常见的癌症。根据美国癌症协会的数据，截至 2023 年，美国约有 238,340 名成年人（117,550 名男性和 120,790 名女性）被诊断出患有肺癌，约 127,070 名成年人（67,160 名男性和 59,910 名女性）死亡。肺癌占所有癌症死亡的五分之一，使其成为美国癌症死亡的主要原因。这些统计数据包括小细胞肺癌和非小细胞肺癌。 NSCLC 是最常见的肺癌类型，占所有肺癌诊断的 81%。在美国，所有类型肺癌的 5 年相对存活率为 23%，对于非小细胞肺癌，男性和女性的 5 年相对存活率分别为 23% 和 33%。在美国，建议以一种称为低剂量螺旋或螺旋电脑断层扫描（CT 或 CAT）扫描的测试来筛检肺癌。预防服务工作小组 (USPSTF) 建议，50-80 岁、有 20 包或以上吸烟史或在过去 15 年内戒烟的人每年应进行低剂量 CT 扫描筛检肺癌。根据数位策略办公室管理的白宫官方网站 Whitehouse.gov 于 2023 年 5 月发布的报告，社区癌症中心协会 (ACCC) 和阿斯特捷利康正在建立合作伙伴关係，以开发和实施透过「农村阿巴拉契亚肺癌筛检计划”，以人为本和可持续的方法来增加美国农村地区的肺癌筛检。阿巴拉契亚地区（包括整个西维吉尼亚州和其他 12 个州的部分地区）的癌症死亡率比美国其他地区高 10%。该计划的目标是将肺癌的五年存活率提高一倍。此类措施正在促进美国北美肺癌筛检市场的成长。

北美肺癌筛检市场收入及 2030 年预测（百万美元）

北美肺癌筛检市场细分

北美肺癌筛检市场按癌症类型、技术、年龄层、最终用户和国家细分。

根据癌症类型，北美肺癌筛检市场分为非小细胞肺癌（NSCLC）和小细胞肺癌。 2022 年，非小细胞肺癌 (NSCLC) 细分市场在北美肺癌筛检市场中占据更大份额。

根据技术，北美肺癌筛检市场分为胸部X光检查、低剂量电脑断层扫描（LDCT）、液体切片等。 2022 年，低剂量电脑断层扫描 (LDCT) 领域在北美肺癌筛检市场中占据最大份额。

根据年龄组，北美肺癌筛检市场分为50岁及以上及50岁以下。2022年，50岁及以上细分市场在北美肺癌筛检市场中占据较大份额。

根据最终用户，北美肺癌筛检市场分为医院、诊断中心等。 2022年，医院部门在北美肺癌筛检市场中占据最大份额。

按国家/地区划分，北美肺癌筛检市场分为美国、加拿大和墨西哥。 2022年，美国在北美肺癌筛检市场占据主导地位。

西门子股份公司、荷兰皇家飞利浦公司、佳能公司、美敦力公司、GE HealthCare、Nuance Communications Inc、LungLife AI, Inc、Intelerad Medical Systems、bioAffinity Technologies, Inc 和 CSV Health 是北美肺癌筛检领域的一些领先公司市场。

Lung cancer is among the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis for lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are encouraged to undergo routine testing to detect the formation of cancerous growth in their lungs. According to estimates by the American Cancer Society for lung cancer in the US for 2023, about 238,340 new lung cancer cases were registered; of these, 120,790 in women and 117,550 in men were reported. Thus, the rising incidence of lung cancer worldwide is contributing to the initiation of lung cancer screening programs, which is, in turn, driving the market growth.

North America Lung Cancer Screening Market Overview

The North America, Lung Cancer Screening Market is segmented into the US, Canada, and Mexico. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and awareness of side effects of cigarette smoking among people. Also, rising government support for screening has led to the further growth of the market.

In North America, the US holds a significant share of the North America Lung Cancer Screening Market . The market growth in this country is primarily driven by the increasing incidence of lung cancer and government initiatives. Lung cancer is the second most common cancer in both men and women in the US. As per the American Cancer Society, Inc., as of 2023, approximately 238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer, and ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung Cancer accounts for 1 in 5 of all cancer death, making it a leading cause of cancer death in the US. These statistics include both small cell lung cancer and NSCLC. NSCLC is the most common type of lung cancer, accounting for 81% of all lung cancer diagnoses. For all types of lung cancer in the US, the 5-year relative survival rate is 23%, and for NSCLC, the 5-year relative survival rate for men and women is 23% and 33%, respectively. In the US, screening for lung cancer is recommended with a test called a low-dose helical or spiral computed tomography (CT or CAT) scan. Preventive Services Task Force (USPSTF) recommends that people aged 50-80, with a history of smoking 20 pack years or more, or who have quit within the past 15 years should go through screening for lung cancer with low-dose CT scans each year. As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca are entering into a partnership to develop and implement person-centered and sustainable approaches to increase lung cancer screening in rural America through the "Rural Appalachian Lung Cancer Screening Initiative." The cancer mortality rate in the Appalachian region, including all of West Virginia and parts of 12 other states, is 10% higher than that in the rest of the US. The aim of this initiative is to double the five-year survival rate for lung cancer. Such initiatives are contributing to the North America Lung Cancer Screening Market growth in the US.

North America Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)

North America Lung Cancer Screening Market Segmentation

The North America lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the North America lung cancer screening market is segmented into non-small cell lung cancer (NSCLC), and small cell lung cancer. The non-small cell lung cancer (NSCLC) segment held a larger share of the North America lung cancer screening market in 2022.

Based on technology, the North America lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Low dose computed tomography (LDCT) segment held the largest share of the North America lung cancer screening market in 2022.

Based on age group, the North America lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the North America lung cancer screening market in 2022.

Based on end user, the North America lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the North America lung cancer screening market in 2022.

Based on country, the North America Lung Cancer Screening Market is segmented into the US, Canada, and Mexico. The US dominated the North America lung cancer screening market in 2022.

Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare, Nuance Communications Inc, LungLife AI, Inc, Intelerad Medical Systems, bioAffinity Technologies, Inc, and CSV Health are some of the leading companies operating in the North America lung cancer screening market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Lung Cancer Screening Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in North America Lung Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America Market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Lung Cancer Screening Market - by Technology
- 1.3.2 North America Lung Cancer Screening Market - by Cancer Type
- 1.3.3 North America Lung Cancer Screening Market - by Age Group
- 1.3.4 North America Lung Cancer Screening Market - by End User
- 1.3.5 North America Lung Cancer Screening Market - by Country

2. North America Lung Cancer Screening Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Lung Cancer Screening Market - Market Landscape

4.1 Overview
4.2 North America PEST Analysis
4.3 Expert's Opinion

5. North America Lung Cancer Screening Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Lung Cancer Incidences
- 5.1.2 Increasing Government Support
5.2 Market Restraints
- 5.2.1 High Cost of Lung Cancer Screening Tests
5.3 Market Opportunities
- 5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
- 5.4.1 Use of Cutting-Edge Technologies
5.5 Impact Analysis

6. Lung Cancer Screening Market - North America Analysis

6.1 North America Lung Cancer Screening Market Revenue Forecast and Analysis

7. North America Lung Cancer Screening Market - Revenue and Forecast to 2028 - By Cancer Type

7.1 Overview
7.2 North America Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer (NSCLC)
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer (NSCLC): North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Mn)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Lung Cancer Screening Market Analysis - by Technology

8.1 Overview
8.2 Low-Dose Computed Tomography (LDCT)
- 8.2.1 Overview
- 8.2.2 Low-Dose Computed Tomography (LDCT): North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.3 Chest X-ray
- 8.3.1 Overview
- 8.3.2 Chest X-ray: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid Biopsy
- 8.4.1 Overview
- 8.4.2 Liquid Biopsy: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)

9. North America Lung Cancer Screening Market Analysis - by Age Group

9.1 Overview
9.2 & Older
- 9.2.1 Overview
- 9.2.2 & Older: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Below 50
- 9.3.1 Overview
- 9.3.2 Below 50: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Lung Cancer Screening Market Analysis - by End User

10.1 Overview
10.2 Hospitals
- 10.2.1 Overview
- 10.2.2 Hospitals: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Diagnostic Centers
- 10.3.1 Overview
- 10.3.2 Diagnostic Centers: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
10.4 Others
- 10.4.1 Overview
- 10.4.2 Others: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Lung Cancer Screening Market - Revenue and Forecast to 2028 - Country Analysis

11.1 North America Lung Cancer Screening Market Overview

12. North America Lung Cancer Screening Market-Industry Landscape

12.1 Recent Growth Strategies
- 12.1.1 Overview

13. Company Profiles

13.1 Intelerad Medical Systems
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Nuance Communications Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GE HealthCare
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Medtronic
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Canon Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Koninklijke Philips NV
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Siemens AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 CVS Health
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 bioAffinity Technologies, Inc.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 LungLife AI, Inc.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms

简介目录图表

List Of Tables

List of Tables

Table 1. US North America Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 2. US North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 3. US North America Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 4. US North America Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 5. Canada North America Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 6. Canada North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada North America Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada North America Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 9. Mexico North America Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 10. Mexico North America Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 11. Mexico North America Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 12. Mexico North America Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 13. Recent Growth Strategies in the North America Lung Cancer Screening Market
Table 14. Glossary of Terms

List Of Figures

List of Figures

Figure 1. North America Lung Cancer Screening Market Segmentation
Figure 2. North America Lung Cancer Screening Market, by Country
Figure 3. North America Lung Cancer Screening Market Overview
Figure 4. Non-Small Cell Lung Cancer Segment Held Largest Share of Cancer Type Segment in North America Lung Cancer Screening Market
Figure 5. North America Expected to Show Remarkable Growth During Forecast Period
Figure 6. North America: PEST Analysis
Figure 7. Experts' Opinion
Figure 8. North America Lung Cancer Screening Market Impact Analysis of Driver and Restraints
Figure 9. North America Lung Cancer Screening Market - Revenue Forecast and Analysis - 2020-2030
Figure 10. North America Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
Figure 11. Non-Small Cell Lung Cancer (NSCLC): North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Small Cell Lung Cancer: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. North America Lung Cancer Screening Market, by Technology, 2022 & 2030 (%)
Figure 14. Low-Dose Computed Tomography (LDCT): North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 15. Chest X-ray: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 16. Liquid Biopsy: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: North America Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Lung Cancer Screening Market, by Age group, 2022 & 2030 (%)
Figure 19. & Older: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Below 50: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. North America Lung Cancer Screening Market, by End User, 2022 & 2030 (%)
Figure 22. Hospitals: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Diagnostic Centers: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: North America Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. North America Lung Cancer Screening Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. North America Lung Cancer Screening Market Revenue Share, by Key Country, (2022 & 2030)
Figure 27. US: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Canada: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Mexico: North America Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)